1. Home
  2. PAR vs SLDB Comparison

PAR vs SLDB Comparison

Compare PAR & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAR Technology Corporation

PAR

PAR Technology Corporation

HOLD

Current Price

$14.54

Market Cap

640.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$6.87

Market Cap

759.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAR
SLDB
Founded
1968
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.6M
759.8M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
PAR
SLDB
Price
$14.54
$6.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$33.20
$16.36
AVG Volume (30 Days)
1.2M
1.1M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.97
EPS
N/A
N/A
Revenue
$455,547,000.00
$8,094,000.00
Revenue This Year
$9.82
N/A
Revenue Next Year
$11.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.16
N/A
52 Week Low
$11.59
$3.07
52 Week High
$72.15
$8.87

Technical Indicators

Market Signals
Indicator
PAR
SLDB
Relative Strength Index (RSI) 50.99 46.21
Support Level $13.85 $6.58
Resistance Level $15.10 $6.97
Average True Range (ATR) 0.98 0.47
MACD 0.04 -0.06
Stochastic Oscillator 49.88 44.56

Price Performance

Historical Comparison
PAR
SLDB

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: